Holen Sie sich die Stockscreener-App
1.06
0.95%
0.01
Handel nachbörslich:
1.04
-0.02
-1.89%
Fibrobiologics Inc Aktie (FBLG) Neueste Nachrichten
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - Sahm
Fibroblast cell therapy avoided psoriasis relapse in FibroBiologics mouse study - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
FBLG Stock Price, Quote & Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FBLG Stock Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics files patent for oral fibroblast delivery system - Investing.com UK
FibroBiologics files patent for oral fibroblast delivery system By Investing.com - Investing.com Australia
New oral cell therapy platform aimed at gut diseases from IBS to Crohn's - Stock Titan
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
TradingKey - TradingKey
Fibrobiologics explores use of fibroblast platform for hantavirus - BioWorld News
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - GlobeNewswire
Severe Hantavirus syndrome lacks drugs, FibroBiologics tests fibroblast therapy - Stock Titan
FibroBiologics | 424B5: Prospectus - Moomoo
FBLG | FibroBiologics, Inc. Common Stock Executive Compensation - Quiver Quantitative
FibroBiologics, Inc. Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
FibroBiologics Expands At-The-Market Equity Offering Capacity - TipRanks
FibroBiologics Grants Stock Options to Key Executives - The Globe and Mail
FibroBiologics (NASDAQ: FBLG) expands $7.5M at-the-market stock offering - Stock Titan
FibroBiologics begins patient enrollment for diabetic foot ulcer trial By Investing.com - Investing.com Australia
FibroBiologics (NASDAQ: FBLG) expands ATM capacity to $7.5M under S-3 - Stock Titan
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study - Sahm
FibroBiologics | DEFA14A: Others - Moomoo
FibroBiologics begins patient enrollment for diabetic foot ulcer trial - Investing.com
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
33 million people have diabetic foot ulcers. FibroBiologics starts a trial - Stock Titan
FibroBiologics grants stock options to CEO Pete O’Heeron and CFO Jason D. Davis - TradingView
[8-K] FibroBiologics, Inc. Reports Material Event - Stock Titan
FibroBiologics (FBLG) seeks approval for warrant shares and 2026 equity incentive plan - Stock Titan
FibroBiologics reports preclinical burn wound treatment results _newTouch_By Investing.com - Investing.com South Africa
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer Davis Jason - Moomoo
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer GARCIA RUBEN A - Moomoo
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer O'HEERON PETE - Moomoo
FibroBiologics reports preclinical burn wound treatment results By Investing.com - Investing.com South Africa
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):